RG 100204
Alternative Names: RG-100204Latest Information Update: 29 Aug 2023
At a glance
- Originator Lund University
- Developer Apoglyx
- Class Antibacterials; Antihyperglycaemics; Antiseptics; Small molecules
- Mechanism of Action AQP9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Sepsis; Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2023 RG 100204 is available for licensing as of 28 Jun 2023. https://apoglyx.com/rd-portfolio/
- 28 Jun 2023 Preclinical trials in Sepsis in Sweden (PO) (Apoglyx pipeline, June 2023)
- 28 Jun 2023 Preclinical trials in Type 2 diabetes mellitus in Sweden (PO) (Apoglyx pipeline, June 2023)